Welcome back, DERM Community.
Selena Gomez announced her lupus diagnosis publicly in 2015 after treatment that included chemotherapy, and in 2017 underwent a kidney transplant for lupus nephritis, with her friend Francia Raisa as donor. Her disease was organ-threatening from the start. Most lupus is not.
For most patients, the first sign is on the skin, and the first clinician to see it is not a rheumatologist.
The Lupus Foundation of America estimates about 1.5 million Americans have some form of lupus (a widely cited figure; population registries suggest lower prevalence for SLE specifically).
Skin involvement occurs in 70 to 80 percent of patients at some point, and cutaneous lupus without systemic disease is at least as common as SLE.
Recognizing the skin patterns, and knowing which tests help and which mislead, is where primary care determines the trajectory.
Five mistakes primary care teams make with lupus skin
1. Calling the malar rash rosacea, or calling rosacea lupus.
The acute cutaneous lupus malar rash is a flat or slightly raised erythema across the cheeks and nasal bridge that spares the nasolabial folds.
Rosacea involves the folds, adds papules and pustules, and flushes with heat, alcohol, and spicy food.
Seborrheic dermatitis is scaly and lives in the folds.
The fold is the fastest discriminator on exam. Lupus malar rash is also photosensitive and typically appears with systemic symptoms: arthralgia, fatigue, fever, oral ulcers.
Practical tip: look at the nasolabial folds. Spared means think lupus. Involved with pustules means think rosacea. Ask about sun exposure and joint pain.
2. Ordering an ANA on every patient with fatigue and a rash.
ANA positivity in the US population rose from about 11 percent in 1988 to nearly 16 percent by 2012 in NHANES data.
A positive ANA at low titer in a patient without clinical features has a very low positive predictive value for lupus and generates anxiety, referrals, and sometimes inappropriate treatment.
Under the 2019 EULAR/ACR criteria, ANA at 1:80 or higher is an entry criterion, not a diagnosis; classification requires weighted clinical and immunologic features on top of it.
Practical tip: order ANA when there is a clinical syndrome: photosensitive rash, inflammatory arthritis, serositis, unexplained cytopenia, or proteinuria. Do not order it for isolated fatigue or a nonspecific rash. If positive, add anti-dsDNA, anti-Smith, complements, CBC, urinalysis.
3. Missing drug-induced subacute cutaneous lupus.
Subacute cutaneous lupus erythematosus presents as annular or papulosquamous, scaly, photodistributed plaques on the upper back, chest, shoulders, and extensor arms, usually sparing the face.
A substantial fraction of SCLE is drug-induced, and the offenders are common primary care prescriptions: hydrochlorothiazide, terbinafine, proton pump inhibitors, calcium channel blockers, ACE inhibitors, and TNF inhibitors.
Onset can be weeks to years after starting the drug. Anti-Ro/SSA is typically positive.
Practical tip: new photodistributed annular plaques in a patient on a thiazide or PPI: stop the drug if feasible, check anti-Ro, refer to dermatology. Resolution after withdrawal can take months.
4. Treating discoid lupus as a slow problem.
Discoid lesions are coin-shaped plaques with adherent scale, follicular plugging, and central atrophy, favoring the scalp, ears, and face. They scar. On the scalp, they cause permanent alopecia.
The window for preventing scarring is early, and the standard of care is potent topical or intralesional corticosteroids plus hydroxychloroquine, with strict photoprotection.
Roughly 5 to 20 percent of patients with discoid lupus progress to SLE, so baseline systemic screening is warranted, but the urgency is the scarring.
Practical tip: discoid lesions on the scalp or face are a prompt dermatology referral, not a routine one. Start photoprotection immediately.
5. Not counseling on sun and smoking.
Ultraviolet exposure triggers and worsens every form of cutaneous lupus, and photosensitivity is often to UVA, which passes through window glass.
Broad-spectrum SPF 50 or higher, daily, with reapplication, is treatment rather than advice. Smoking is independently associated with more severe cutaneous lupus and with reduced response to antimalarials.
Patients on hydroxychloroquine also need baseline and annual retinal screening after five years (or sooner with risk factors), and the dose should not exceed 5 mg/kg of actual body weight.
Practical tip: at every lupus visit, ask about sunscreen use, ask about smoking, and confirm the ophthalmology schedule.
Practical reset checklist
Cheek erythema: check the nasolabial folds, ask about sun and joints
ANA only with a clinical syndrome; interpret with titer, pattern, and specific antibodies
Photodistributed annular plaques: review thiazides, PPIs, terbinafine, CCBs; check anti-Ro
Discoid lesions on scalp or face: expedited dermatology referral, photoprotection now
Every cutaneous lupus patient: SPF 50 daily, smoking cessation, baseline urinalysis and CBC
Hydroxychloroquine: dose 5 mg/kg or less, retinal screening on schedule
"It is more important to know what sort of person has a disease than to know what sort of disease a person has."
Interested in reaching our 8,000+ subscribers?
Click here to learn more!
Some Jobs We Think You’re Gonna Love:
Want to Go Deeper?
👋🏻 Thank you for being here, DERM community!
Check the fold before you check the antibody. Consider escalating or referring when:
Hormonal scores are high and the patient has irregular periods, hirsutism, or sudden adult onset (evaluate for androgen excess, including PCOS)
Nodulocystic lesions are scarring or haven't responded to adequate topical and oral therapy
The diagnosis is uncertain after one treatment cycle
Thank you for reading Beneath the Surface, and for the care you bring to every skin complaint that walks through your door.
Many of our topics start with questions from readers, so if there's a presentation you keep seeing in clinic and want us to cover, reply to this email and tell us!
DERM Community | Derm for Primary Care Team
